share_log

Mural Oncology To Host Virtual Investor Day, Provide New Clinical Insight Into Trial Design, Statistical Assumptions, And Progress Of Late-stage Trials Of Nemvaleukin

Benzinga ·  Sep 26 19:20

Key data readouts for the company's late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma.

IND submission for Mural's IL-18 program planned for Q4 2025

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment